Trevogrumab

Trevogrumab
Monoclonal antibody
Type	?
Source	Human
Target	growth differentiation factor 8
Clinical data
Other names	REGN1033
ATC code	none;
Identifiers
CAS Number	1429201-24-0;
ChemSpider	none;
UNII	87T4327873;
KEGG	D11242;
Chemical and physical data
Formula	C6374H9884N1696O2018S46
Molar mass	144037.80 g·mol−1

Trevogrumab (INN;^[1] development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia.

This drug was developed by Regeneron Pharmaceuticals, Inc.^[2]

References

^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Trevogrumab, American Medical Association.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[WHOList113-1] World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).

[2] Statement On A Nonproprietary Name Adopted By The USAN Council - Trevogrumab, American Medical Association.

[1]

[2]

Trevogrumab

References

€4.95